EDTA dependent pseudothrombocytopenia caused by antibodies against the cytoadhesive receptor of platelet gpIIB-IIIA.

A Casonato, A Bertomoro, E Pontara, D Dannhauser, A R Lazzaro, A Girolami

University of Padua Medical School, Institute of Medical Semeiotics, Italy.

AIMS--To clarify the mechanisms involved in the development of EDTA dependent pseudothrombocytopenia, particularly the platelet receptors. METHODS--Platelets were measured in 33 patients with pseudothrombocytopenia, using different anticoagulants to collect blood samples (direct test). The results were compared with the counts obtained by adding patients' serum or immunoglobulins to normal blood samples (indirect test). The role of platelet function was explored using ASA, PGE1, and apyrase as platelet inhibitors. The contribution of platelet receptor/s was investigated using antigens to gpIb-IX and gpIIb-IIIa monoclonal antibodies. Immunoglobulin class was estimated by the ability of IgG, IgA, and IgM antibodies to prevent platelet clumping. RESULTS--Agglutinating antibodies were IgA in 40%, IgG in 30%, and IgM in 10% of patients studied. Both patients' serum and immunoglobulins induced platelet clumping in normal samples anticoagulated with EDTA (indirect test). This was prevented by incubation of blood samples at 37 degrees C and almost completely inhibited by the platelet inhibitors ASA, PGE1, and apyrase. Pseudothrombocytopenia was also entirely prevented by an antigen to gpIIb-IIIa monoclonal antibody that recognises fibrinogen and the von Willebrand factor binding site. Pseudothrombocytopenia was almost completely abolished after the addition of RGD peptide, the recognition sequence of cytoadhesive proteins. CONCLUSIONS--These findings suggest that EDTA dependent pseudothrombocytopenia is caused by agglutinating antibodies that recognise cytoadhesive receptors on platelet gpIIb-IIIa and that an efficient platelet metabolism is required.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Mylonakis, M. E., Leontides, L., Farmaki, R., Kostoulas, P., Koutinas, A. F., Christopher, M. (2008). Effect of anticoagulant and storage conditions on platelet size and clumping in healthy dogs. jvdi 20: 774-779 [Abstract] [Full Text]  
• Kittisupamongkol, W. (2008). Incidence and Prognostic Significance of Thrombocytopenia in Patients Receiving Heparin Therapy. Arch Intern Med 168: 2170-2170 [Full Text]  
• Wills, T. B., Wardrop, K. J. (2008). Pseudothrombocytopenia Secondary to the Effects of EDTA in a Dog. Journal of the American Animal Hospital Association 44: 95-97 [Abstract] [Full Text]  
• Nair, S. K., Shah, R., Petko, M., Keogh, B. E. (2007). Pseudothrombocytopenia in cardiac surgical practice. ICVTS 6: 565-566 [Abstract] [Full Text]  
• Yoshikawa, T., Nakanishi, K., Maruta, T., Takenaka, D., Hirota, S., Matsumoto, S., Saigo, K., Ohno, Y., Fujii, M., Sugimura, K. (2006). Anticoagulant-Induced Pseudothrombocytopenia Occurring after Transcatheter Arterial Embolization for Hepatocellular Carcinoma. Jpn J Clin Oncol 36: 527-531 [Abstract] [Full Text]  
• Levin, T., Segal, J., Moll, S., Harrington, R. A., Simoons, M. L., Topol, E. J. (1999). Eptifibatide in Acute Coronary Syndromes. NEJM 340: 60-61 [Full Text]  
• Makris, P. E., Foka, Z., Gerotziafas, G. T., Kioumi, A., Pithara, E. (1998). Pseudothrombocytopenia: A Rare Phenomenon. CLIN APPL THROMB HEMOST 4: 167-169 [Abstract]